European Society Of Cardiology In Brief
This article was originally published in The Gray Sheet
Executive SummaryStudy shows better TAVI benefit in women
You may also be interested in...
FDA warns OHM Pharma for promoting topical formula containing homeopathic ingredients as teething product for infants. The firm also warned about drug and supplements GMP violations and was an easy target for FDA following release of draft guidance outlining its enforcement priorities.
Richard Pazdur, FDA's oncology chief, reiterates the breakthrough therapy designation is for agency-sponsor communication and not an investor tool.